Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes

NCT02490098 | Withdrawn Phase 2

• 1 other identifier: CLASS-13
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Current intensive insulin therapy in T1D involves prandial insulin boluses depending on the carbohydrate content of each ingested meal. Carbohydrate content of ingested meals is the main determinant of post-meal glucose excursion. Therefore, accurate carbohydrate counting is a critical aspect of managing postprandial blood glucose levels in type 1 diabetes in order to avoid too much or too little insulin resulting in hypoglycemia and hyperglycemia, respectively. Precision of carbohydrate counting is associated with better glycemic control. However, accurate carbohydrate counting is a challenging task for many patients with type 1 diabetes. Recent developments of continuous glucose sensors and insulin infusion pumps have motivated the research toward "closed-loop'' strategies to regulate glucose levels in patients with type 1 diabetes. In a closed-loop strategy, the pump insulin infusion rate is altered based on a computer generated recommendation that rely on continuous glucose sensor readings. A dual-hormone closed-loop strategy has also been recently proposed to regulate glucose levels. In a dual-hormone strategy, subcutaneous insulin delivery is accompanied by subcutaneous glucagon infusion. Postprandial meal glucose control with closed-loop strategy still needs some improvements. The objective of this study is to test in outpatient unrestricted settings whether, in the context of closed-loop strategy, conventional meal carbohydrate counting could be reduced to a simplified qualitative meal size estimation without a significant degradation in overall glycemic control in children and adult patients with type 1 diabetes. The investigators hypothesize that 1) dual-hormone closed-loop strategy with qualitative meal size estimation is equivalent to dual-hormone closed-loop strategy with CHO counting in terms of mean glucose; 2) single-hormone closed-loop strategy with qualitative meal size estimation is equivalent to single-hormone closed-loop strategy with CHO counting in terms of mean glucose;

Conditions

Type 1 Diabetes

Keywords

Type 1 diabetes; Closed-loop system; Artificial pancreas; Insulin; Glucagon; Hypoglycemia; Postprandial glucose

Outcome Measures

Primary Outcomes (1)

• Mean day-and-night glucose levels

  6 days

Secondary Outcomes (14)

• Percentage of time of glucose levels between 4.0 and 8.0 mmol/L

  6 days

• Percentage of time of glucose levels between 4.0 and 10.0 mmol/L

  6 days

• Percentage of time of glucose levels above 10.0 mmol/L

  6 days

• Percentage of time of glucose levels above 14.0 mmol/L

  6 days

• Percentage of time of glucose levels spent below 4.0 mmol/L

  6 days

Study Arms (5)

Single-hormone closed-loop strategy with full boluses

ACTIVE COMPARATOR

Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.

Other: 6-day intervention with single-hormone closed-loop strategy; Drug: Insulin; Device: Continuous Glucose Monitoring System Enlite sensor®, Medtronic; Device: Insulin pump MiniMed® Paradigm® Veo™, Medtronic

Dual-hormone closed-loop strategy with full boluses

ACTIVE COMPARATOR

Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) and Glucagon (Eli Lilly) will be infused using two separate subcutaneous infusion pumps (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.

Other: 6-day intervention with dual-hormone closed-loop strategy; Drug: Insulin; Drug: Glucagon; Device: Continuous Glucose Monitoring System Enlite sensor®, Medtronic; Device: Insulin pump MiniMed® Paradigm® Veo™, Medtronic

Single-hormone closed-loop strategy with partial boluses

ACTIVE COMPARATOR

Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). For this strategy, meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO. The meal size assessment will be done by the patient.

Other: 6-day intervention with single-hormone closed-loop strategy; Drug: Insulin; Device: Continuous Glucose Monitoring System Enlite sensor®, Medtronic; Device: Insulin pump MiniMed® Paradigm® Veo™, Medtronic

Dual-hormone closed-loop strategy with partial boluses

ACTIVE COMPARATOR

Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) and Glucagon (Eli Lilly) will be infused using two separate subcutaneous infusion pumps (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). For this strategy, meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO. The meal size assessment will be done by the patient.

Other: 6-day intervention with dual-hormone closed-loop strategy; Drug: Insulin; Drug: Glucagon; Device: Continuous Glucose Monitoring System Enlite sensor®, Medtronic; Device: Insulin pump MiniMed® Paradigm® Veo™, Medtronic

Sensor-augmented pump therapy

ACTIVE COMPARATOR

Subjects will use sensor-augmented pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels. Patient's usual fast acting insulin analog will be infused using a subcutaneous insulin infusion pump. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.

Other: 6-day intervention with sensor-augmented pump therapy; Drug: Insulin; Device: Continuous Glucose Monitoring System Enlite sensor®, Medtronic; Device: Insulin pump MiniMed® Paradigm® Veo™, Medtronic

Interventions

6-day intervention with sensor-augmented pump therapy OTHER

One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. Participants will adjust their insulin delivery as per their standard practice; including temporary basal and correction boluses. Participants will have access to their finger-stick glucose measurements and will be advised to measure their glucose level as per their standard practice. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol. Participants will use sensor-augmented pump therapy for 6 days.

Sensor-augmented pump therapy

6-day intervention with single-hormone closed-loop strategy OTHER

One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.

Single-hormone closed-loop strategy with full boluses; Single-hormone closed-loop strategy with partial boluses

6-day intervention with dual-hormone closed-loop strategy OTHER

One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. Participants will have to install a second pump containing glucagon. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.

Dual-hormone closed-loop strategy with full boluses; Dual-hormone closed-loop strategy with partial boluses

Insulin DRUG

Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)

Dual-hormone closed-loop strategy with full boluses; Dual-hormone closed-loop strategy with partial boluses; Sensor-augmented pump therapy; Single-hormone closed-loop strategy with full boluses; Single-hormone closed-loop strategy with partial boluses

Glucagon DRUG

Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.

Dual-hormone closed-loop strategy with full boluses; Dual-hormone closed-loop strategy with partial boluses

Continuous Glucose Monitoring System Enlite sensor®, Medtronic DEVICE

Enlite sensor®, Medtronic

Dual-hormone closed-loop strategy with full boluses; Dual-hormone closed-loop strategy with partial boluses; Sensor-augmented pump therapy; Single-hormone closed-loop strategy with full boluses; Single-hormone closed-loop strategy with partial boluses

Insulin pump MiniMed® Paradigm® Veo™, Medtronic DEVICE

MiniMed® Paradigm® Veo™, Medtronic

Dual-hormone closed-loop strategy with full boluses; Dual-hormone closed-loop strategy with partial boluses; Sensor-augmented pump therapy; Single-hormone closed-loop strategy with full boluses; Single-hormone closed-loop strategy with partial boluses

Eligibility Criteria

• Age: 8 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Males and females ≥ 8 years old.
• Clinical diagnosis of type 1 diabetes for at least one year.
• The subject will have been on insulin pump therapy for at least 3 months and currently using a fast actin insulin analog (Lispro, Aspart or Guilisine).
• Last (less than 3 months) HbA1c ≤ 10%.
• Currently using carbohydrate counting as the meal insulin dose strategy.
• Live in the area of Montreal

You may not qualify if:

• Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator.
• Recent (\< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.
• Pregnancy.
• Severe hypoglycemic episode within 1 month of screening.
• Agents affecting gastric emptying (Motilium®, Prandase®, Victoza®, Byetta® and Symlin®) as well as oral anti-diabetic agents (Metformin, SGLT-2 inhibitors and DPP-4 inhibitors) if not at a stable dose for 3 months. Otherwise, these medications are acceptable and will be kept stable during the entire protocol.
• Oral steroids unless patients present a low stable dose (e.g. 10 mg or less of prednisone per day or physiological doses, less than 35 mg/day, of hydrocortisone Cortef®). Inhale steroids at stable dose in the last month are acceptable.
• Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator (e.g. unstable psychiatric condition).
• Failure to comply with team's recommendations (e.g. not willing to change pump parameters, follow algorithm's suggestions, etc).
• Living or planned travel outside Montreal (\> 1h of driving) area during closed-loop procedures.

Sponsors & Collaborators

• Institut de Recherches Cliniques de Montreal: lead
• Juvenile Diabetes Research Foundation: collaborator

Study Sites (1)

Institut de recherches cliniques de Montréal

Montreal, Quebec, H2W 1R7, Canada

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1; Insulin Resistance; Hypoglycemia

Interventions

Methods; Insulin; Glucagon

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases; Hyperinsulinism

Intervention Hierarchy (Ancestors)

Investigative Techniques; Proinsulin; Insulins; Pancreatic Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins; Proglucagon

Study Officials

• Rémi Rabasa-Lhoret

  Institut de recherches cliniques de Montréal

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor of Medicine

Study Record Dates

• First Submitted: July 1, 2015
• First Posted: July 3, 2015
• Study Start: January 1, 2018
• Primary Completion: July 1, 2018
• Study Completion: July 1, 2018
• Last Updated: October 27, 2017

Record last verified: 2017-10

Locations

CA (1)